Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Erlotinib (Tarceva™)

Last Updated: 02/16/18

Status: Currently a NF2 Clinical Trial


Chemical Structure, Erlotinib

Trade Name: Tarceva™
Synonyms: Tarceva, 183321-74-6, CHEBI:114785,
N-(3-Ethynylphenyl)-6,
7-bis(2-methoxyethoxy)quinazolin-4-amine,
nchembio866-comp3,
Pharmaceutical Companies: Genetech, Roche, and OSI Pharmaceuticals/Astellas
Legal Status: ℞ - Prescription Only
Administered By: Pill - Oral
Tumor Target: Intracranial Schwannoma
Protein Target: TKI Inhibitor
Formula: C22H23N3O4
IUPAC: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy
)quinazolin-4-amine
ChemSpider: CSID:154044
PubChem: CID 176870

NF2 Trial

  • Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 - www.ClinicalTrials.gov
  • A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-Small-Cell Lung Cancer (NSCLC) - www.ClinicalTrials.gov
  • Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib - www.ClinicalTrials.gov
  • Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy - www.ClinicalTrials.gov

Side Effects

Minor

Side Effects may Increase, tell your Doctor if you experience any of the following:

  • Diarrhea
  • Loss of Appetite
  • Nausea
  • Vomiting
  • Heartburn
  • Gas
  • Constipation
  • Stomach Pain
  • Mouth Sores
  • Weight Loss
  • Extreme Tiredness
  • Headache
  • Bone or Muscle Pain
  • Depression
  • Anxiety
  • Numbness, Burning, or Tingling of the Hands or Feet
  • Swelling of the Arms, Hands, Feet, Ankles, or Lower Legs
  • Darkening of Skin
  • Hair Loss
  • Change in Appearance of Hair and Nails

Serious Side Effects

  • Shortness of Breath
  • Cough
  • Fever or Chills
  • Chest Pain or Pressure
  • Pain in the Arms, Neck, or Upper Back
  • Rapid, Irregular, or Pounding Heartbeat
  • Slow or Difficult Speech
  • Dizziness or Faintness
  • Weakness or Numbness of an Arm or Leg
  • Unusual Bruising or Bleeding
  • Black and Tarry or Bloody Stools
  • Bloody Vomit or that looks like Coffee Grounds
  • Dry Mouth
  • Decreased Urination
  • Dark Urine
  • Pale or Yellow Skin
  • Redness, Warmth, Pain, Tenderness, or Swelling in One Leg
  • Skin Issues -
    • Rash (may look like acne and may affect the skin on the face, upper chest, or back
    • Blistering
    • Peeling
    • Dry
    • Cracked Skin
    • Itching
    • Tenderness
    • Burning
  • Eye Issues -
    • Dry Eyes
    • Red Eyes
    • Eye Pain
    • Irritated Eyes
    • Blurred Vision
    • Sunken Eyes
    • Growth of Eyelashes on the inside of the eyelid

Sources

  1. Van, JJ Gompel, et al. "Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas." Neurosurgery (2017).
    Source: http://europepmc.org/abstract/med/29309638 | DOI: 10.1093/neuros/nyx516

  2. Benhamouche, Samira, et al. "Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver." Genes & development 24.16 (2010): 1718-1730.
    Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030413/ | DOI: 10.1101/gad.1964810

  3. Plotkin, Scott R., et al. "Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients." Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 31.7 (2010): 1135.
    Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030413/#R10 | DOI: 10.1097/MAO.0b013e3181eb328a

  4. Plotkin, Scott R., et al. "Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy." Nature Reviews Clinical Oncology 5.8 (2008): 487.
    Source: https://www.nature.com/articles/ncponc1157 | DOI: 10.1038/ncponc1157